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ABSTRACT: 
Nanovesicles have superior benefits over conventional dosage forms because 
the vesicles can act as drug containing reservoirs and can entrap both hydrophilic and 
lipophilic drugs. Surface modification of nanovesicles can adjust the drug release rate 
and the affinity for the target site.In recent years, Span 60 based nanovesicles have 
been the object of growing scientific attention as an alternative potential drug delivery 
system to conventional liposomes. The aim of present work was firstly to study the 
effects of different PEGylated edge activator (Myrj 52 and Myrj 59) on Span 60 based 
nanovesicles. Nanovesicles were prepared using Span 60 alone or in combination with 
Myrj 52 or Myrj 59by employing the ethanol injection method. Myrj 52andMyrj 
59are hydrophilic nonionic surfactants were used to modify the surface of the 
developedvesicles. Dynamic light scattering was used to determine the size, zeta 
potential and polydispersity index of the nanovesicles formulation. The vesicles were 
also characterized for entrapment efficiency and in vitro release. In current work, we 
have shown that the surface modified nanovesicles vesicles are a homogenous and 
monodisperse vesicular population.Also, the modified nanovesicles are characterized 
by smaller particles size compared to non-modified vesicles.All the modified 
nanovesicles were acquired negative value of zeta potential and showed accepted in 
vitro release of TN from nanovesicles, followed higuchi models as drug release 
mechanism.In conclusion, these surface modified nanovesicles could be used as a 
potential drug carrier for a variety of drugs. 
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INTRODUCTION 
The self-assembly of non-ionic surfactants into nanovesicles represents an 
interesting opportunity to achieve vesicular colloidal drug carriers, which resemble 
liposomes in their architecture and can be used as an effective alternative to liposomal 
drug carriers 1.Nanovesicles prepared from non-ionic surfactant are chemically stable, 
easy stored and of lower cost compared to liposome forming phospholipids 2.The 
encapsulation of drug inside the nanovesicles can improve the therapeutic activity of 
the drug molecules by protecting the drug from biological environment,delayed 
clearance from the circulation and restricting effects to target cells 3. The vesicle 
formation may depend on the HLB value; thus the guidance offered by the HLB 
number is useful in the evaluation of new classes of compounds for their vesicles 
forming ability. Span 60as hydrophobic nonionic surfactant (HLB 4.7) was found to 
be compatible with vesicle formation4. 
Modification of the vesicles composition or surface can adjust the drug release 
rate and the affinity for the target site 5, 6.A series of research articles were described 
smart nanovesicles application in drugtargeting and delivery7.Spanlastic systems 
recently developed Kakkar and Kauras novel nanovesicles drug carriers based on non-
ionic surfactants and explored their potential for the ocular and dermal delivery of 
ketoconazole. The spanlastic systems consisted of Span 60, as a non-ionic lipophilic 
surfactant, along with an edge activator (Tween 60 and Tween 80). The edge 
activators are hydrophilic surfactant molecules that provide flexibility to the lipid 
bilayers of spanlastic systems by inducing pores and causing destabilization of these 
membranes 8. Also, long circulation vesicleswere recently developed from surface 
modification of nanovesicles by a hydrophilic carbohydrate or polymer, usually a 
lipid derivative of polyethyleneglycol (PEG), to help evade recognition. The result, 
called stealth effect, is ascribed to steric stabilization of the vesicles by the polymer, 
combined with the additional hydrophilicity that can prevent the adsorption of blood 
components onto the vesicles surface 9. 
Theophylline (TN) is a widely used methylxanthine drug in the treatment of 
the patients with moderate to severe reversible bronchospasm. The exploitation of 
extended release formulation is necessary because of the side effects in clinical 
practice and associate central nervous system of the fluctuations of serum 
theophylline level 10. The serum concentration of theophylline must be maintained 
  
within a relatively narrow range to achieve optimal therapeutic benefits while 
avoiding toxic side effects 11. Theophylline is rapidly and completely absorbed from 
liquidpreparation, capsules and uncoated tablets 12.  
The aims of the present work to investigate the effect of different PEGylated 
edge activator (PEA) on Span 60 based nanovesicles taking theophylline as a model 
drug. Myrj 52 (polyethylene glycol 2000 monostearate) and Myrj 59 (polyethylene 
glycol 4400 monostearate) were selected as PEA in development of modified 
nanovesicles. Nanovesicleswere characterized by dynamic light scattering in order to 
determine vesicles size, zeta potential and polydispersity index. We also determined 
the entrapment efficiency and in vitro release properties of the modified nanovesicles. 
The physicochemical characterization of the modified nanovesicles was compared 
with those obtained by non-modified nanovesicles.  
MATERIALS AND METHODS: 
 TN was a kind gift from El-Nile company for pharmaceuticals and chemical 
industries (Cairo, Egypt) 
 Sorbitan monostearate (Span 60), Polyoxyl 40 stearate (Myrj 52) and Polyoxyl 
100 stearate (Myrj 59) were purchased from Sigma Chemical Co. (St. Louis, 
USA).  
 Spectra Por© semi-permeable membrane (MWCO 12,000–14,000) was obtained 
from Spectrum Laboratories Inc. (CA, USA). 
 All other chemicals and solvents were of analar grade and obtained from El-Nasr 
Company for pharmaceutical chemicals, Cairo, Egypt. 
Preparation of TN loaded nanovesicles 
TN loaded modified nanovesicles were prepared by the ethanol injection 
method as described by Kakkar and Kaur with some modifications. Briefly, Span 60 
was dissolved in ethanol and injected into a preheated aqueous phase in which TN and 
PEA (Myrj 52or Myrj 59) was previously dissolved. The organic phase to the aqueous 
phase ratio was fixed at 1:5. The Span 60: PEA ratios were 9:1, 4:1, 7:3, 3:2 and 1:1, 
respectively. The nanovesicles were formed spontaneously and turned the resulting 
hydro alcoholic solution slightly turbid. Continuous stirring of the latter solution on a 
magnetic stirrer was performed to allow complete evaporation of ethanol 13. 
Sonication was performed for 3 min, to promote the development of fine modified 
nanovesicles. The non-modified nanovesicles were prepared by same method but 
without adding the PEA. The composition of the investigated formulae is shown in 
Table 1. 
Characterization of TN loaded nanovesicles 
  
Total drug content 
Isopropyl alcohol was chosen as a suitable solvent for disrupting the prepared 
vesicles. Aqueous nanovesicles dispersion (1 ml) was disrupted by shaking for 15 min 
in sufficient quantity of isopropyl alcohol and the absorbance of withdrawn aliquot 
was recorded at 273 nm. 
Determination of entrapment efficiency of TN in nanovesicles dispersions  
Samples (1 ml) of nanovesicles dispersions prepared were frozen for 24 h at -
20°C in Eppendorf tubes. The frozen samples were removed from the freezer and let 
to thaw at room temperature, then centrifuged at 20000 rpm for 60 min at 4°C. Two 
times washings with phosphate buffer (pH 6.8) were done for complete removal of 
drug adsorbed on the surface of nanovesicles.  
The supernatant was separated each time from nanovesicles pellets and 
prepared for the assay of free drug. Each result was the mean of three determinations 
(± SD).The drug content was determined spectrophotometrically against phosphate 
buffer (pH 6.8) as blank. The % entrapped TN was calculated according to the 
following equation14. 
                   % Entrapment efficiency=
total amount of drug−un entrapped
total amount of drug
× 100 
Determination of vesicle size, zeta potential and polydispersity index 
The hydrodynamic vesicle diameter (z-average) and the polydispersity index 
(PI) of the systems were evaluated by the dynamic light scattering (DLS) technology 
via a Zetasizer Nano ZS (Malvern instruments; Worcestershire, UK). The technique 
analyzes the fluctuations in light scattering due to the Brownian motion of vesicles 
and consequently estimates z-average. Triplicate measurements were carried out, at 
25±0.5ºC, after appropriate dilution with deionized water to obtain a suitable 
scattering intensity at 90ºwith respect to the incident beam 8. The better PI values 
indicate homogenous vesicle size distribution 15. The zeta potential (ζ) values of the 
systems were determined according to the electrophoretic light scattering (ELS) 
technology using a Laser Doppler Anemometer coupled with the same equipment. 
The technique analyzes the electrophoretic mobility of vesicles under an electric field. 
Triplicate measurements were carried out, at 25±0.5ºC, after appropriate dilution with 
deionized water. 
In vitro drug release studies 
Based on the calculated EE percentages, accurate amounts of the washed 
sediments separated from of nanovesicles suspension were redispersed in water. The 
in vitro release of TN from nanovesicles was determined by the dialysis bag method 16 
  
with slight modification. Briefly, 1 ml of nanovesicles dispersion was transferred in 
dialysis bags with a molecular cut-off 12-14 kDa. The bags were suspended in 100 ml 
of release medium (phosphate buffer pH 7.4). The whole set-up was placed in a 
shaking water bath adjusted to a constant speed of 100 rpm at 37 ± 0.5°C. Samples 
were withdrawn at appropriate time intervals from the outer solution to estimate the 
percentage of drug released. To compensate for sampling, 2 ml of fresh buffer was 
added to the dissolution media. 
Two ml of sample was taken from the outer solution at appropriate time 
intervals, i.e. 1, 2, 3, 4, 5, 6, 7, and 8 h. The drug released percentages were 
determined spectrophotometrically at predetermined λmax. The release studies were 
conducted in triplicate and the mean drug released percentages (±S.D.) were plotted 
versus time. Concurrently, the in vitro release study of an aqueous TN solution (10 
mg/ml) was conducted to investigate the retarding effect of the dialysis tubing.  
Kinetic analysis 
The in vitro drug release data were fitted to three different kinetic models 
which are often used to describe the drug release behavior from nanovesicles, i.e. 
zero-order, first-order and Higuchi models. Stating the proper mode of release is 
based on the correlation coefficient (r) for the linear regression fit of the parameters 
involved, where the highest correlation coefficient represents the actual mode of the 
release 3. 
Statistical analysis 
The data were reported as mean ±S.D. (n = 3) and statistical analysis of the 
data were carried out using one way ANOVA at a level of significant of P< 0.05. 
Ranking the results 
The data obtained from the physicochemical evaluation (PZ, PDI, ZP and EE) 
was ranked and the best formula was selected as nanovesicles model in the 
development of new carrier for drug delivery. Also, the best formula was subjected to 
the following investigations.  
Morphologic examination via transmission electron microscopy (TEM)  
The morphologic examination of the systems was carried out to examine the 
structural attributes such as the lamellarity and the uniformity of size and shape as 
well as to explore the presence of aggregated vesicles 13. A drop of the dispersion was 
diluted 10-fold using deionized water, and then a drop of the diluted dispersion was 
applied to a carbon-coated 300 mesh copper grid and left for 1min to allow some of 
the nanovesicles to adhere to the carbon substrate. The remaining dispersion was 
  
removed by absorbing the drop with the corner of a piece of filter paper and the 
sample was air dried 17. 
Fourier transform-infrared spectroscopy (FT-IR) studies 
The FTIR spectra (range 4000–650 cm−1) were performed for TN, Span 60 and 
PEA using a FT-IR spectrophotometer (spectral resolution of 4 cm−1 and 32 co-added 
scans) equipped with a MIRacleTM ATR device with a single reflection diamond crystal 
(1.8 mm spot size). The samples were deposited on top of a diamond crystal and 
secured with a high-pressure clamp. The average of characteristic peaks of IR 
transmission spectra were recorded from triplicate samples 8. 
Differential scanning calorimetry (DSC) 
For thermal analysis, samples were scanned using DSC and the thermograms 
so generated were evaluated for any significant shift or disappearance/appearance of 
new peaks. Assessment the degree of crystallinity and the presence of possible 
interactions between TN, Span 60 and PEAwere explored by using DSC techniques. 
The calorimeter was calibrated for temperature and heat flow accuracy using the 
melting of pure indium (m.p.156.6°C and ΔH of 25.45 J gm−1). The temperature range 
was from 0 to 300°C with a heating rate of 10°C/min. The gas used was nitrogen with 
a purging rate of 50 ml/min 13. 
Stability studies 
Stability studies were carried out to investigate the leaching of drug from 
nanovesicles during storage. The ability of vesicles to retain the drug was assessed by 
keeping the nanovesicles suspension in sealed glass ampoules (15 ml capacity) at 
25◦C, and 4◦C for 3 months. Samples were withdrawn periodically and analyzed for 
entrapment efficiency and drug content.  
RESULTS AND DISCUSSION: 
Formation of TN-loaded nanovesicles 
Span 60based nanovesicles were successfully prepared, in the presence of 
Myrj52, Myrj 59 or alone, by the ethanol injection method.The method of preparation 
of nanovesicles is based on the simple idea that the mixture of surfactant: alcohol: 
aqueous phase can be used to form nanovesicles dispersions. Many synthetic 
amphiphiles such as nonionic surfactants, quaternary ammonium salts with one, two 
or three chains and long chain fatty acidswere able to form bilayers under favorable 
conditions 14.  A bilayer is normally constituted of a long chain amphiphiles, with a 
hydrophilic head and a hydrophobic tail. The transfer of hydrocarbon chains into 
aqueous medium would accompany a free energy loss originating mainly from 
entropy which drives the organic layer into ordered bilayers 18. 
  
The lipophilic nature of the saturated alkyl chains in Span 60 would permit the 
formation of mono and/or multi-lamellar matrix vesicles. In a parallel line, the surface 
active properties of this surfactant would augment the action of the hydrophilic 
surfactants allowing for a reduction in the interfacial tension and subsequent 
development of fine nanovesicles dispersions  8 . Myrj 52 and Myrj 59 are hydrophilic 
nonionic surfactants with HLB 16.9 and 18.8, respectively 19.The incorporation of 
PEA (Myrj 52 or Myrj 59) can destabilize the vesicular membranes, increase their 
deformability and create systems having different degrees of disruption in packing 
characteristics 20. Furthermore, these hydrophilic surfactants would potentiate the 
elastic nature of the vesicles allowing them to temporarily increase the pore size of the 
biological membranes such that slightly bigger vesicles can squeeze in and promote 
better drug penetration 21. 
Ethanol has positive impacts on the properties of these  nanovesicles  via 
improving the drug partitioning and entrapping within the vesicles 22, via decreasing 
the size of the vesicles by the reduction of the thickness of their  membranes due to 
the membrane condensing ability of ethanol or the formation of a phase with 
interpenetrating hydrocarbon chains and finally via modifying the net charge of the 
system toward a negative zeta potential  resulting in some degree of steric 
stabilization 23.  
Characterization of TN loaded nanovesicles 
Drug content 
The amount of TN added into the nanovesicles dispersions was 5 mg/ml and 
the drug content of the developed formulations was not found to be significantly 
different 
(p< 0.05) from the added amount (Table 2). 
Entrapment efficiency 
In freezing, drug and vesicles are concentrated; particles are closely packed in 
contact with each other resulting in fusion of nanovesicles 24. The EE percentages of 
TN-loaded non-modified nanovesicles dispersion (Nvs11) was 56.60% while the EE 
percentages of TN-loaded surface modified nanovesicles dispersion (Nvs1-Nvs10) 
varied markedly from 76.13% (Nvs1) to 36.42% (Nvs10), as shown in table (2). The 
ANOVA results confirmed that the PEA type and concentration had significant 
impacts (P< 0.05) on the EE% of the developed formulae. Myrj 52 decorated vesicles 
showed significantly higher EE % than the corresponding Myrj 59 decorated ones. 
The significantly higher drug EE percentages of the PEA low concentration (10%) 
dispersions (p< 0.001) could be attributed to the ability of the polar head groups of 
  
PEA to solubilize higher drug amounts via hydrogen bonding with the carboxyl 
groups. In fact, increases the concentrations of PEA above 10% lower drug EE 
percentages were obtained. According to 25, when the PEA concentration reaches a 
certain threshold, vesicles size decrease (SUV) and consequently decrease the EE%. 
Results listed in table (2) showed that nanovesicles developed from Myrj52 
mainly have higher entrapment efficiency than other formulations containing Myrj 
59this could be due to the PEA chemical structure. 
Nanovesicles prepared from Myrj 52 were exhibit high entrapment efficiency this 
could be explained on the basis that the ability of Myrj 52 to form hydrogen bond 
with Span 60 and the increase in Myrj 52 concentration and/or hydrophilicity would 
enhance the bending of these chains to a degree that can affect the tightness of the 
developing vesicular membranes 8. These effects can increase the tendency of TN 
escape and the membrane permeability. 
Vesicle size and polydispersity index (PDI) 
This study shows that the particle size of non-modified nanovesicles (Nvs11) 
was 287.8 nm while the particle size of non-modified nanovesicles formulations lies 
between 54.32-141.7 nm which is a convenient nano-range. Table (3) showed 
significant decrease of particle size upon addition of PEA (Myrj 52&Myrj 59) in 
comparison with Nvs11. Also, significant decrease of particle size upon increasing 
concentration of PEA (Myrj 52&Myrj 59) above 30% and decreasing the 
concentration of Span 60 in comparison with 10-20% of PEA. This indicates that the 
particle size of the prepared nanovesicles was influenced by the type and 
concentration of the PEA. The increase of PEA concentration reduces the size of 
nanovesicles 8. This is attributed to the reduction in the surface tension between the 
aqueous phase and the organic phase and the diminution of the latter one decreases 
the particles size 13. In formulations containing Myrj 52, the particle size was found to 
be higher than formulation containing Myrj 59 at same concentration. This might be 
due to the higher emulsification power of Myrj 59 than Myrj 52. The ANOVA results 
showed that higher edge activator concentration above 30% had significant effects (P 
< 0.05) on the mean vesicle size of the developed spanlastic vesicles. 
Generally, inverse correlations were observed between the PEA concentration 
and the mean vesicle size. This might be attributed to the increasing emulsification 
power encountered with the use of higher concentrations of the PEA. It could be 
inferred that the lower PEA concentrations might be unable to cover the entire vesicle 
surface. Thereby, some vesicles would aggregate till the surface area is decreased to a 
point that the available amount of the PEA was able to coat the entire surface of the 
  
agglomerate and thus forming a stable dispersion.In a parallel line, the increase in the 
vesicle size with increasing Span 60 concentrations was correlated to the insertion of 
more alkyl chains of Span 60 into the hydrophobic domain of the vesicles and the 
subsequent reduction in the interaction between the polar heads of the PEA molecules 
26. 
The obtained PDI values of non-modified nanovesicles was 0.634 and the PDI 
values of modified nanovesicles were lies between 0.248 – 0.531 as shown in table 
(3), which shows that the particle size populations of the Nvs1and Nvs2 are very 
homogeneous. These good results of particle size and PDI of TN loaded surface 
modified nanovesicles. 
Zeta potential 
The surface charge of the vesicles controls their stability in nanovesicles 
formulations through strong electrostatic repulsions between the particles27.Table(3) 
shows that the Nvs1, Nvs2 and Nvs11 in this study display a sufficiently high 
negative zeta potential that ensures that the nanoparticles will disperse very well in the 
aqueous media and that the nanosuspension will have a very good stability and 
tolerance against aggregation 28.  
It was clear from table (3)that the zeta potential of non-modified nanovesicles 
is -30.41meVand all the modified nanovesicles were acquired negative value of zeta 
potential lie between -5.67 meV to -27.1 meV. Generally the negative zeta potential 
values are expected due to the membrane condensing ability of ethanol or the 
formation of a phase with interpenetrating hydrocarbon chains and finally via 
modifying the net charge of the system toward a negative zeta potential  resulting in 
some degree of steric stabilization 23. 
 All the developed nanovesicles were negatively charged which is in agreement 
with similar results obtained by tayeland colleagues, which predict a good stability of 
the prepared nanovesicles. The results showed that the highest zeta potential value (-
30.41 meV) was obtained in case of the formulation Nvs11 while the lowest zeta 
potential value (-5.67 meV) was obtained in case of the formulation Nvs4. The 
difference in zeta potential values could be explained by the fact that the stability is 
dependent on the combination of the Span 60 with PEA. This is attributed to 
differences in the PEAconcentration which leading to differences in surface coverage. 
In vitro release profile of theophylline 
Figure (1and 2) showed that the release profiles of TN from modified and non-
modified nanovesicles of different PEA contents is an apparently biphasic release 
process. Rapid drug leakage was observed during the initial phase ranged from 25 – 
  
57% of the entrapped drug was released from various formulations in the first 30 min 
of nanovesicles suspended in 100 ml of phosphate buffer pH 7.4. However, during the 
following 8 h a slow release occurred in which most of TN was released from 
different nanovesicles preparations (about 73-99%).This could be explained on the 
basis that the drug is mainly incorporated between the fatty acid chains in the lipid 
bilayers of nanovesicles. This leads to rapid ionization and release upon dispersing 
nanovesicles in increased buffer volumes until reaching equilibrium. Also, it has been 
reported that, a highly ordered lipid particles cannot accommodate large amounts of 
drug and is the reason for drug expulsion 29.   
Different nanovesicles dispersions were tested for the drug release behavior in 
order to evaluate the effect of PEA/Span 60 ratio on TN release. The observed 
differences in release characteristics could be attributed to the EPA type and 
concentration in the formulation. Figures (1-2) showed that the non-modified 
nanovesicles formulations displayed 50.67% released after 8 h and the modified 
nanovesicles containing 10% EPA (Nvs1and Nvs6) displayed the lowest extent of 
drug release after 8hrs (73.22% and 73.21%) in phosphate buffer pH 7.4. In addition 
to, Nvs10 showed higher release rates after 8hrs (about 99.5%) at phosphate buffer 
pH7.4 compared to other formulations. The increase in release rates of TN from 
nanovesicles formulation upon increase PEA content was statistically significant (P< 
0.05). 
The correlation between the PEA concentration and the drug released 
percentages could be explained with respect to the vesicle diameters, the amount of 
the dissolved drug in the lipophilic part increase as the radius of the vesicles increase. 
Also, at higher EPA, the smaller vesicles would reduce the drug diffusional distance 
and consequently promote higher drug dissolution rates 30.Figures (1-2) showed the 
difference in the release rates between the nanovesicles containing Myrj 52 and 
nanovesicles containing Myrj 59. Significantly (P< 0.05) higher drug released 
percentages were achieved with nanovesicles containing Myrj 59 at concentration 
above 30% (more than 93% released). Statistical analysis showed non-significant 
differences in the release percentages of TN from Nvs1 and Nvs6 in different pH 
systems after 8 h (P =0.601).The result is in accordance with tayeland colleagues who 
reported that increasing edge activator concentration can disrupt the regular linear 
structure of the vesicular membrane and increase the drug release.  
Kinetic analysis of the release data of TN- loaded nanovesicles 
  
The obtained release data were tested according to zero, first order kinetic and 
diffusion controlled model. The pattern of TN release from nanovesicles formulations 
was in favor of higuchi models. 
Ranking the results 
From the total rank order as shown in table (4), it can be concluded that Nvs1 
is the best one according to the data obtained from the physicochemical evaluation 
(PZ, PDI, ZP and EE).Also, Nvs1showed accepted total drug content and invitro 
release of TN from nanovesicles, followed higuchi modelsas drug release mechanism. 
So, Nvs1was selected as drug carrier system and subject to further characterization. 
Morphological Characterization 
The morphological appearance of Nvs1 was visualized using transmission 
electron microscope (TEM) and the obtained photographs were illustrated in figure 
(3). The examined nanovesicles appeared as small unilamellar (SUV), spherical 
nanovesicles under the TEM. The morphologic examination of the dispersions 
confirmed the development of nanospherical vesicles having narrow size 
distributions; in accordance with the results of the particle size measurements. The e 
smaller vesicles were almost unilamellar with larger internal aqueous cores. 
FT-IR studies 
FT -IR spectroscopic studies were employed to explore the possible 
intermolecular interactions between TN, Span 60 and Myrj 52. The FT-IR spectra of 
TN, Span 60, Myrj 52 and physical mixture are displayed in figure (4). The 
characteristic peaks of TN were compared with the peaks obtained for their 
formulation. It was observed that similar characteristic peaks appear with minor 
differences, the peaks appearing in region 2824–2712 cm−1 are attributed to N=CH3 
bond. The C-N stretching vibrations are seen at 1049 cm−1, while the one that 
appeared at 1243 cm−1 is assigned to aromatic C=O stretching vibrations. A slight 
shift of bands position from1717 cm-1 to 1712 cm−1 and from 1667 cm−1 from 1663 
cm−1attributed to CO-N-(R)-CO theophylline characteristic group 
The bands at 3430–3450 cm−1 assigned to OH groups and also band at 2882 
cm−1 assigned to CH2 symmetric stretching because of the possible interactions 
between components by hydrogen bonding. The bands at 2862 cm-1and 2923 cm-1 
could be attributed to C—H stretching vibrations of methyl and/or methylene groups 
of Span 60 and Myrj 52, respectively. The FT-IR spectrum of the physical mixture 
revealed that the characteristic bands of TN did not disappear or exhibit major shifts. 
Furthermore, no new bands were formed. These findings point out the lack of 
  
considerable intermolecular inter actions between TN, Span60 and Myrj 52 as shown 
in figure (4). 
Differential scanning calorimetry (DSC) 
Figure (5) depicts various DSC thermograms obtained during the study. Pure 
TN showed a sharp endothermic peak at 273°C. Thermogram of Span 60 exhibits an 
endothermic peak with onset at 44.62°C and maximum occurrence at 52.24°C. Myrj 
52 showed an endothermal peak at 52.6°C. The DSC thermograms of developed 
nanovesicles showed new endothermal peak at 106.4°C, indicating an increase in the 
phase transition temperature of nanovesicles upon loading with TN. These findings 
could point out the possible dispersion of TN throughout the nanovesicular carrier in 
an amorphous state 8. The TN peak was disappeared upon incorporation of TN into 
nanovesicles proving complete entrapping of drug into the vesicles. 
Stability studies 
The results of stability studies are compiled in figure (6). Stability of vesicles 
is referred to in terms of % loss in drug content and % of drug entrapped in vesicles 
over a period of 1, 2 and 3 months of storage. Extent of drug leakiness upon storage in 
refrigerator was significantly low; while at room temperature there was an appreciable 
drug loss and decreased in entrapment efficiency (10%& 30%). Hence the system 
needs to be refrigerated for use as is the case with all other vesicular systems (Plessis 
et al., 1996). Developed modified nanovesicles were sufficiently stable under 
refrigerated condition and fulfill ICH guidelines showing 2.09% loss in drug content 
and 5% decreased inentrapment efficiency at 3 months. However, the formulations are 
not recommended to be stored at room temperature. 
CONCLUSIONS: 
From the above mentioned results, we can conclude that; Surface modified 
nanovesicles were successfully prepared by the ethanol injection method. The particle 
size obtained for the investigated modified nanovesicles formulations were in the 
submicron range (from 54.3 -141.7nm) withPDI less than 0.5 and negative charge. 
Modified nanovesicles showed high drug encapsulation efficiencies and higher release 
rate. From the statistical analysis to the obtained results of nanovesicles formulation, 
increased amount of PEA caused decrease in the particle size, zeta potential and the 
entrapment efficiency % for the developed nanovesicles formulation. The TEM 
images of the modified nanovesicles, showing the formation of uniform, regular round 
spherical in shape and smooth surface nanovesicles with no evidence of aggregation. 
Finally, the surface modified nanovesicles are a promising drug carrier system. 
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Table (1): The composition (mg/ml) of TN loaded nanovesicles. 
Formula Span 60 (mg) Myrj 52 (mg) Myrj 59(mg) TN (mg) 
Nvs1 45 5 - 5 
Nvs2 40 10 - 5 
Nvs3 35 15 - 5 
Nvs4 30 20 - 5 
Nvs5 25 25 - 5 
Nvs6 45 - 5 5 
Nvs7 40 - 10 5 
Nvs8 35 - 15 5 
  
Nvs9 30 - 20 5 
Nvs10 25 - 25 5 
Nvs11 50 0 0 5 
 
Table (2):Total drug content and entrapment efficiency% of nanovesicles (each result 
is the mean ± SD, n = 3) 
Formula Total drug content Entrapment Efficiency % 
Nvs1 4.98±0.37 76.13±0.54 
Nvs2 4.91±0.55 62.40±1.02 
Nvs3 4.90±0.75 50.66±0.83 
Nvs4 4.88±1.09 44.340.99 
Nvs5 4.85±1.02 40.16±0.49 
Nvs6 4.95±0.29 67.20±0.09 
Nvs7 4.90±0.10 57.65±1.11 
Nvs8 4.87±0.81 42.01±0.68 
Nvs9 4.86±1.06 37.56±0.96 
Nvs10 4.84±0.83 36.42±0.99 
Nvs11 4.81±1.23 56.60±1.06 
 
 
 
Table (3): The mean vesicles size, polydispersity index and zeta potential of 
nanovesicles formulation. 
Formula Mean vesicles 
size (nm) 
PDI Mean Zeta 
potential (meV) 
Nvs1 139.3 0.325 -27.1 
Nvs2 141.7 0.248 -26.7 
Nvs3 103.8 0.362 -11.1 
Nvs4 76.63 0.400 -5.67 
Nvs5 73.47 0.531 -11.3 
Nvs6 131.7 0.397 -6.44 
Nvs7 97.66 0.429 -6.36 
Nvs8 90.42 0.488 -7.76 
Nvs9 75.02 0.436 -6.95 
Nvs10 54.32 0.399 -6.24 
Nvs11 287.8 0.634 -30.41 
 
  
 
Figure (1): Effects of Myrj 52 concentration on TN release from nanovesicles at pH 
7.4. 
 
 
 
 
 
Figure (2): Effects of Myrj59 concentration on TN release from nanovesicles at pH 
7.4. 
 
Table (4): Rank order for the physicochemical evaluation of TN loaded nanovesicles. 
Formula EE % rank  
Order 
particle size 
rank order 
PDI rank 
 Order 
Zeta potential 
rank order 
Total rank 
Order 
Nvs1 1 9 2 2 14 
Nvs2 3 10 1 3 17 
Nvs3 6 7 3 5 21 
Nvs4 7 4 6 11 28 
Nvs5 9 2 10 4 25 
Nvs6 2 8 4 8 22 
  
Nvs7 4 6 7 9 26 
Nvs8 8 5 9 6 28 
Nvs9 10 3 8 7 28 
Nvs10 11 1 5 10 27 
Nvs11 5 11 11 1 28 
 
 
 
 
 
 
 
 
 
Figure (3): TEM micrographs of vesicles at 10000x magnification of Nvs1. 
 
 
Figure (4): FT-IR spectra of TN, Span 60, Myrj 52 and physical mixture 
 
 
 
  
 
Figure (5): DSC thermogram of TN, Span 60, Myrj 52 and  TN-loaded nanovesicles. 
 
 
 
 
Figure (6): Effects of storage temperature on; total drug content (A) and entrapment 
efficiency (B). 
